Meng, one of the directors of UCM makes a significant on market purchase of 1m shares for $144,643.

He holds over 20% of the company's shares.

DIRECTOR TRANSACTIONS
27 May 21: Meng +1.0m for $144,643 @ $0.145 [32.37m]

SprioSonic AIR approved for European CE Mark.  The SpiroSonic AIR is used for the assessment of asthma, COPD, occupational lung disease and post COVID syndrome. The SpiroSonic AIR is accurate, easy to use, and provides research quality non-invasive lung function testing for patients with asthma, COPD, occupational lung disease and post COVID syndrome, and can be used in the lab, clinic or home. 

Last month, the China NMPA approved the BP+.

These regulatory approvals provide future revenue streams and are positive for the company.  However, how much revenue is generated is still to be seen.

22 Oct 19:

Medical device - Non-invasive cardiovascular and pulmonary monitoring devices

CEO/Chair holds 20% of company.

Entered chinese market.

Approaching profitability.  Revenue growing at 29% p.a. over the last 6 years.